These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28390038)

  • 21. Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma.
    Khare T; Khare S; Angdisen JJ; Zhang Q; Stuckel A; Mooney BP; Ridenhour SE; Gitan RS; Hammoud GM; Ibdah JA
    Int J Cancer; 2020 Sep; 147(5):1461-1473. PubMed ID: 32115688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease expression and clinicopathological significance of miR-148a with poor survival in hepatocellular carcinoma tissues.
    Ajdarkosh H; Dadpay M; Yahaghi E; Pirzaman ER; Fayyaz AF; Darian EK; Mokarizadeh A
    Diagn Pathol; 2015 Aug; 10():135. PubMed ID: 26248880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical staining reveals differential expression of ACSL3 and ACSL4 in hepatocellular carcinoma and hepatic gastrointestinal metastases.
    Ndiaye H; Liu JY; Hall A; Minogue S; Morgan MY; Waugh MG
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32286604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
    Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
    Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.
    Dong F; Yang Q; Wu Z; Hu X; Shi D; Feng M; Li J; Zhu L; Jiang S; Bao Z
    Biomed Pharmacother; 2019 Jun; 114():108856. PubMed ID: 30981109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
    Shimada S; Mogushi K; Akiyama Y; Furuyama T; Watanabe S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Arii S; Tanabe M; Wands JR; Tanaka S
    EBioMedicine; 2019 Feb; 40():457-470. PubMed ID: 30598371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of AKT kinases as unfavorable prognostic factors for hepatocellular carcinoma by a combination of expression profile, interaction network analysis and clinical validation.
    Zhang Y; Guo X; Yang M; Yu L; Li Z; Lin N
    Mol Biosyst; 2014 Feb; 10(2):215-22. PubMed ID: 24247267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of heterogeneous redox responses in hepatocellular carcinoma patients using network analysis.
    Benfeitas R; Bidkhori G; Mukhopadhyay B; Klevstig M; Arif M; Zhang C; Lee S; Cinar R; Nielsen J; Uhlen M; Boren J; Kunos G; Mardinoglu A
    EBioMedicine; 2019 Feb; 40():471-487. PubMed ID: 30606699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of KIF1B mRNA in hepatocellular carcinoma tissues correlates with poor prognosis.
    Yang SZ; Wang JT; Yu WW; Liu Q; Wu YF; Chen SG
    World J Gastroenterol; 2015 Jul; 21(27):8418-24. PubMed ID: 26217094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
    Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.
    Chen L; Guan H; Gu C; Cao Y; Shao J; Wang F
    Tumour Biol; 2016 Feb; 37(2):2497-507. PubMed ID: 26385772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of ACSF gene family as therapeutic targets and immune-associated biomarkers in hepatocellular carcinoma.
    Zhao Z; Liu M; Xu Z; Cai Y; Peng B; Liang Q; Yan Y; Liu W; Kang F; He Q; Hong Q; Zhang W; Li J; Peng J; Zeng S
    Aging (Albany NY); 2022 Oct; 14(19):7926-7940. PubMed ID: 36205594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SH2D4A is frequently downregulated in hepatocellular carcinoma and cirrhotic nodules.
    Quagliata L; Andreozzi M; Kovac M; Tornillo L; Makowska Z; Moretti F; Heim MH; Heinimann K; Piscuoglio S; Terracciano LM
    Eur J Cancer; 2014 Mar; 50(4):731-8. PubMed ID: 24315626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reanalysis of microRNA expression profiles identifies novel biomarkers for hepatocellular carcinoma prognosis.
    Wang Z; Ding Q; Li Y; Liu Q; Wu W; Wu L; Yu H
    Tumour Biol; 2016 Nov; 37(11):14779-14787. PubMed ID: 27633066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma stage: an almost loss of fatty acid metabolism and gain of glucose metabolic pathways dysregulation.
    Balakrishnan K
    Med Oncol; 2022 Oct; 39(12):247. PubMed ID: 36209296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fatty acid metabolic enzyme acyl-CoA thioesterase 8 promotes the development of hepatocellular carcinoma.
    Hung YH; Chan YS; Chang YS; Lee KT; Hsu HP; Yen MC; Chen WC; Wang CY; Lai MD
    Oncol Rep; 2014 Jun; 31(6):2797-803. PubMed ID: 24788990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Clinicopathologic Significance of BAF250a (ARID1A) Expression in Hepatocellular Carcinoma.
    Zhao J; Chen J; Lin H; Jin R; Liu J; Liu X; Meng N; Cai X
    Pathol Oncol Res; 2016 Jul; 22(3):453-9. PubMed ID: 26589513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Up-regulation of miR-9 expression predicate advanced clinicopathological features and poor prognosis in patients with hepatocellular carcinoma.
    Cai L; Cai X
    Diagn Pathol; 2014 Dec; 9():1000. PubMed ID: 25552204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress.
    Wang MD; Wu H; Huang S; Zhang HL; Qin CJ; Zhao LH; Fu GB; Zhou X; Wang XM; Tang L; Wen W; Yang W; Tang SH; Cao D; Guo LN; Zeng M; Wu MC; Yan HX; Wang HY
    Oncotarget; 2016 Feb; 7(6):6711-26. PubMed ID: 26744319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.